These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37992389)

  • 1. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
    Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
    Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
    Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study.
    Cacciapuoti S; Battista T; Potestio L; Scalvenzi M; Megna M; Ruggiero A
    Clin Exp Dermatol; 2024 Oct; ():. PubMed ID: 39400048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.
    Burlando M; Castelli R; Cozzani E; Parodi A
    Drugs Context; 2021; 10():. PubMed ID: 34104197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis.
    Heim J; Vasquez JG; Bhutani T; Koo J; Mathew J; Gogineni R; Ferro T; Bhatia N
    J Drugs Dermatol; 2024 Aug; 23(8):612-618. PubMed ID: 39093661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA; Seemann C; Gerdes S; Mrowietz U
    Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Berenguer-Ruiz S; Aparicio-Domínguez M; Herranz-Pinto P; Ruíz-Villaverde R; López-Ferrer A; Santos-Juanes J; Rodríguez Fernández-Freire L; Hospital-Gil M; Arias-Santiago S; Carretero-Hernández G; Mateu-Puchades A; Ferran M; Del Alcázar E; Santos-Alarcón S; Garcia-Latasa de Aranibar FJ; Belinchón-Romero I; González-Cantero Á; Ruíz-Genao D; Eiris-Salvado N; Rocamora-Durán V; Rivera-Diaz R; de la Cueva P; Daudén E; Salgado-Boquete L; Llamas-Velasco M;
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2517-2525. PubMed ID: 37625815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study.
    Heim J; Vasquez JG; Schenkel B; Bhatia N
    J Drugs Dermatol; 2023 Aug; 22(8):754-760. PubMed ID: 37556515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.
    Campione E; Lambiase S; Gaeta Shumak R; Galluzzo M; Lanna C; Costanza G; Borselli C; Artosi F; Cosio T; Tofani L; Dattola A; Di Daniele F; Bianchi L
    Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting.
    Bhatia N; Heim J; Vasquez JG; Bhutani T; Schenkel B; Gogineni R; Koo J
    J Dermatolog Treat; 2024 Dec; 35(1):2310631. PubMed ID: 39038815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
    Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
    Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
    Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.
    Torres T; Varela P; Mendes Bastos P; Magina S; Henrique M; Ferreira P
    Drugs Context; 2024; 13():. PubMed ID: 38510314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 18. A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice.
    Burlando M; Salvi I; Parodi A; Cozzani E
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2645-2652. PubMed ID: 39192037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
    Bagel J; Novak K; Nelson E
    J Drugs Dermatol; 2023 Aug; 22(8):766-772. PubMed ID: 37556520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.